Literature DB >> 22173517

A randomized, double-blind, placebo-controlled trial of selective digestive decontamination using oral gentamicin and oral polymyxin E for eradication of carbapenem-resistant Klebsiella pneumoniae carriage.

Lisa Saidel-Odes1, Hana Polachek, Nehama Peled, Klaris Riesenberg, Francisc Schlaeffer, Yafa Trabelsi, Seada Eskira, Baha Yousef, Rozalia Smolykov, Shlomi Codish, Abraham Borer.   

Abstract

OBJECTIVE: To assess the effectiveness of selective digestive decontamination (SDD) for eradicating carbapenem-resistant Klebsiella pneumoniae (CRKP) oropharyngeal and gastrointestinal carriage.
DESIGN: A randomized, double-blind, placebo-controlled trial with 7 weeks of follow-up per patient.
SETTING: A 1,000-bed tertiary-care university hospital. PATIENTS: Adults with CRKP-positive rectal swab cultures.
METHODS: Patients were blindly randomized (1 :1) over a 20-month period. The SDD arm received oral gentamicin and polymyxin E gel (0.5 g 4 times per day) and oral solutions of gentamicin (80 mg 4 times per day) and polymyxin E (1 x 10(6) units 4 times per day for 7 days). The placebo arm received oral placebo gel 4 times per day and 2 placebo oral solutions 4 times per day for 7 days. Strict contact precautions were applied. Samples obtained from the throat, groin, and urine were also cultured.
RESULTS: Forty patients (mean age ± standard deviation, 71 ± 16 years; 65% male) were included. At screening, greater than or equal to 30% of oropharyngeal, greater than or equal to 60% of skin, and greater than or equal to 35% of urine cultures yielded CRKP isolates. All throat cultures became negative in the SDD arm after 3 days (P < .0001). The percentages of rectal cultures that were positive for CRKP were significantly reduced at 2 weeks. At that time, 16.1% of rectal cultures in the placebo arm and 61.1% in the SDD arm were negative (odds ratio, 0.13; 95% confidence interval, 0.02-0.74; P < .0016). A difference between the percentages in the 2 arms was still maintained at 6 weeks (33.3% vs 58.5%). Groin colonization prevalence did not change in either arm, and the prevalence of urine colonization increased in the placebo arm.
CONCLUSIONS: This SDD regimen could be a suitable decolonization therapy for selected patients colonized with CRKP, such as transplant recipients or immunocompromised patients pending chemotherapy and patients who require major intestinal or oropharyngeal surgery. Moreover, in outbreaks caused by CRKP infections that are uncontrolled by routine infection control measures, SDD could provide additional infection containment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22173517     DOI: 10.1086/663206

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  51 in total

1.  Carbapenem-Resistant Enterobacteriaceae: Laboratory Detection and Infection Control Practices.

Authors:  Eva-Brigitta Kruse; Ute Aurbach; Hilmar Wisplinghoff
Journal:  Curr Infect Dis Rep       Date:  2013-10-12       Impact factor: 3.725

2.  Management of carbapenem resistant Klebsiella pneumoniae infections in stem cell transplant recipients: an Italian multidisciplinary consensus statement.

Authors:  Corrado Girmenia; Claudio Viscoli; Alfonso Piciocchi; Laura Cudillo; Stefano Botti; Antonio Errico; Loredana Sarmati; Fabio Ciceri; Franco Locatelli; Maddalena Giannella; Matteo Bassetti; Carlo Tascini; Letizia Lombardini; Ignazio Majolino; Claudio Farina; Francesco Luzzaro; Gian Maria Rossolini; Alessandro Rambaldi
Journal:  Haematologica       Date:  2015-04-10       Impact factor: 9.941

3.  Efficacy and safety of fecal microbiota transplantation for decolonization of intestinal multidrug-resistant microorganism carriage: beyond Clostridioides difficile infection.

Authors:  Young Kyung Yoon; Jin Woong Suh; Eun-Ji Kang; Jeong Yeon Kim
Journal:  Ann Med       Date:  2019-09-13       Impact factor: 4.709

4.  Selective digestive tract decontamination and spread of colistin resistance: antibiotic prophylaxis is not a substitute for hygiene.

Authors:  Wolfgang A Krueger; Alexandra Heininger; Béatrice Grabein; Klaus Unertl; Miguel Sánchez-García
Journal:  Antimicrob Agents Chemother       Date:  2014-06       Impact factor: 5.191

5.  Reply to "selective digestive tract decontamination and spread of colistin resistance: antibiotic prophylaxis is not a substitute for hygiene".

Authors:  Teysir Halaby; Nashwan Al Naiemi; Christina M J E Vandenbroucke-Grauls
Journal:  Antimicrob Agents Chemother       Date:  2014-06       Impact factor: 5.191

6.  Oral gentamicin gut decontamination for prevention of KPC-producing Klebsiella pneumoniae infections: relevance of concomitant systemic antibiotic therapy.

Authors:  Carlo Tascini; Francesco Sbrana; Sarah Flammini; Enrico Tagliaferri; Fabio Arena; Alessandro Leonildi; Ilaria Ciullo; Francesco Amadori; Antonello Di Paolo; Andrea Ripoli; Russell Lewis; Gian Maria Rossolini; Francesco Menichetti
Journal:  Antimicrob Agents Chemother       Date:  2014-01-13       Impact factor: 5.191

7.  Colonization of liver transplant recipients with KPC-producing Klebsiella pneumoniae is associated with high infection rates and excess mortality: a case-control analysis.

Authors:  C Lübbert; D Becker-Rux; A C Rodloff; S Laudi; T Busch; M Bartels; U X Kaisers
Journal:  Infection       Date:  2013-11-12       Impact factor: 3.553

8.  The pros, cons, and unknowns of search and destroy for carbapenem-resistant enterobacteriaceae.

Authors:  Prashini Moodley; Andrew Whitelaw
Journal:  Curr Infect Dis Rep       Date:  2015-06       Impact factor: 3.725

Review 9.  Trends in human fecal carriage of extended-spectrum β-lactamases in the community: toward the globalization of CTX-M.

Authors:  Paul-Louis Woerther; Charles Burdet; Elisabeth Chachaty; Antoine Andremont
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

10.  Infectious Considerations in the Pre-Transplant Evaluation of Cirrhotic Patients Awaiting Orthotopic Liver Transplantation.

Authors:  Allison Mah; Alissa Wright
Journal:  Curr Infect Dis Rep       Date:  2016-01       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.